<b>Introduction and Objectives:</b> There is limited evidence on the role of glucagon-like peptide-1 receptor agonists in the interplay between cardiovascular disease, chronic kidney disease, and metabolic dysfunction. This evidence concerns the gene GLP1R and chronic kidney disease.